Results 81 to 90 of about 6,260 (129)

[Mechanisms and clinical research progress of mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Wang N, Xu ZL, Liu DH.
europepmc   +1 more source

[Conversion therapy for hepatoid adenocarcinoma of the stomach: A case report]. [PDF]

Beijing Da Xue Xue Bao Yi Xue Ban
Li J, Chen L, Tang J, Wu Y, Wang A.
europepmc   +1 more source

[A compulsory course in clinical treatment of burn patients: pain and analgesia]. [PDF]

Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi
Nie FF.
europepmc   +1 more source

[Recent advances in individualized treatment for pediatric high-risk B-cell acute lymphoblastic leukemia]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Li YQ, Wang YJ, Li ZZ, Ni JX.
europepmc   +1 more source

[Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance]. [PDF]

Zhongguo Fei Ai Za Zhi
Zhan S, Chen P, Lv T, Song Y.
europepmc   +1 more source

[Tumor-secreted dentin sialophosphoprotein induces oxaliplatin resistance in colorectal cancer through an integrin αvβ3-dependent pathway]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Liu C, Ning Z, Wu J, Liu W, Lin C, Xu J, Zhou R, Zhao L.   +7 more
europepmc   +1 more source

氩激光小梁成形术治疗开角型青光眼——4年随访报告

Zhongshan Daxue xuebao. Yixue kexue ban, 1990
用氩激光小梁成形术(ALT)治疗79例105眼开角型青光眼的4年疗效。总有效率78％,平均眼压下降1.34kPa(10.04mmHg),4年内疗效稳定。全部病例均为最大耐受量药物治疗无效拟作滤过性手术者,ALT术后83％病例在4年内可避免作滤过性手术。失败的23眼中有21眼在ALT后半年内眼压回升,另2眼在第3年回升,18眼(17％)须作滤过性手术。ALT术后42.9％的病例其用药种数减少。年岁较大(>60岁 ...
doaj  

[Guidelines for the diagnosis and management of first relapsed multiple myeloma in China (2026)]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association, Chinese Myeloma Committee-Chinese Hematology Association.   +3 more
europepmc   +1 more source

[Advances in targeted therapies for chronic spontaneous urticaria]. [PDF]

Zhejiang Da Xue Xue Bao Yi Xue Ban
Zhou L, Hu C, Wang S, Zhang R.
europepmc   +1 more source

[Chinese expert consensus on the use of standardized second-line drugs for primary hepatocellular carcinoma]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Translational Medicine Branch, China Association of Gerontology and Geriatrics, Society of Hepatology, Beijing Medical Association, Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology.   +5 more
europepmc   +1 more source